{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": [], "KeywordList": [], "GeneralNote": [], "PMID": "16550222", "DateCompleted": {"Year": "2006", "Month": "04", "Day": "24"}, "DateRevised": {"Year": "2020", "Month": "09", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2006", "Month": "01", "Day": "16"}], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "1741-427X", "JournalIssue": {"Volume": "3", "Issue": "1", "PubDate": {"Year": "2006", "Month": "Mar"}}, "Title": "Evidence-based complementary and alternative medicine : eCAM", "ISOAbbreviation": "Evid Based Complement Alternat Med"}, "ArticleTitle": "The alkaloid alstonine: a review of its pharmacological properties.", "Pagination": {"StartPage": "39", "EndPage": "48", "MedlinePgn": "39-48"}, "Abstract": {"AbstractText": ["Indole compounds, related to the metabolism of tryptophan, constitute an extensive family, and are found in bacteria, plants and animals. Indolic compounds possess significant and complex physiological roles, and especially indole alkaloids have historically constituted a class of major importance in the development of new plant derived drugs. The indole alkaloid alstonine has been identified as the major component of a plant-based remedy, used in Nigeria to treat mental illnesses by traditional psychiatrists. Although it is certainly difficult to compare the very concept of mental disorders in different cultures, the traditional use of alstonine is remarkably compatible with its profile in experimental animals. Even though alstonine in mice models shows a psychopharmacological profile closer to the newer atypical antipsychotic agents, it also shows important differences and what seems to be an exclusive mechanism of action, not entirely clarified at this point. Considering the seemingly unique mode of action of alstonine and that its traditional use can be viewed as indicative of bioavailability and safety, this review focuses on the effects of alstonine in the central nervous system, particularly on its unique profile as an antipsychotic agent. We suggest that a thorough understanding of traditional medical concepts of health and disease in general and traditional medical practices in particular, can lead to true innovation in paradigms of drug action and development. Overall, the study of this unique indole alkaloid may be considered as another example of the richness of medicinal plants and traditional medical systems in the discovery of new prototypic drugs."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Laborat\u00f3rio de Etnofarmacologia, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. elaine.elisabetsky@gmail.com"}], "Identifier": [], "LastName": "Elisabetsky", "ForeName": "E", "Initials": "E"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Costa-Campos", "ForeName": "L", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Evid Based Complement Alternat Med", "NlmUniqueID": "101215021", "ISSNLinking": "1741-427X"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Williams JE. Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on u\u00f1a de gato and sangre de grado. Altern. Med. Rev. 2001;6:567\u201379.", "ArticleIdList": ["11804547"]}, {"Citation": "Cano A, Alcaraz O, Arnao MB. Free radical-scavenging activity of indolic compounds in aqueous and ethanolic media. Anal Bioanal Chem. 2003;376:33\u20137.", "ArticleIdList": ["12734615"]}, {"Citation": "Cordell GA, Quinn-Beattie ML, Farnsworth NR. The potencial of alkaloids in drug discovery. Phytother Res. 2001;15:183\u2013205.", "ArticleIdList": ["11351353"]}, {"Citation": "Costa-Campos L, Elisabetsky E, Lara DR, Carlson TJ, King SR, Ubilas R, et al. Antipsychotic profile of alstonine: ethnopharmacology of a traditional Nigerian botanical remedy. An Acad Bras Cienc. 1999;71:189\u2013201.", "ArticleIdList": ["10412490"]}, {"Citation": "Iwu MM, Klayman DL. Evaluation of the in vitro antimalarial activity of Picralima nitida extracts. J Ethnopharmacol. 1992;36:133\u20135.", "ArticleIdList": ["1608269"]}, {"Citation": "Noble RL. The discovery of the vinca alkaloids\u2014chemotherapeutic agents against cancer. Biochem Cell Biol. 1990;68:1344\u201351.", "ArticleIdList": ["2085431"]}, {"Citation": "Kweifio-Okai G. Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: I. J Ethnopharmacol. 1991;33:263\u20137.", "ArticleIdList": ["1921424"]}, {"Citation": "Ezeamuzie IC, Ojinnaka MC, Uzogara EO, Oji SE. Anti-inflammatory, antipyretic and anti-malarial activities of a West African medicinal plant\u2014Picralima nitida. Afr J Med Med Sci. 1994;23:85\u201390.", "ArticleIdList": ["7839951"]}, {"Citation": "Wosu LO, Ibe CC. Use of extracts of Picralima nitida bark in the treatment of experimental trypanosomiasis: a preliminary study. J Ethnopharmacol. 1989;25:263\u20138.", "ArticleIdList": ["2747261"]}, {"Citation": "Nasser AM, Court WE. Stem bark alkaloids of Rauvolfia caffra. J Ethnopharmacol. 1984;11:99\u2013117.", "ArticleIdList": ["6471882"]}, {"Citation": "Perlman WR, Weickert CS, Akil M, Kleinman JE. Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. J Psychiatry Neurosci. 2004;29:287\u201393.", "ArticleIdList": ["PMC446223", "15309045"]}, {"Citation": "Lyne J, Kelly BD, O'Connor WT. Schizophrenia: a review of neuropharmacology. Ir J Med Sci. 2004;173:155\u20139.", "ArticleIdList": ["15693386"]}, {"Citation": "Costa-Campos L, Lara DR, Nunes DS, Elisabetsky E. Antipsychotic-like profile of alstonine. Pharmacol Biochem Behav. 1998;60:133\u201341.", "ArticleIdList": ["9610935"]}, {"Citation": "Bourin M, Poisson L, Larousse C. Piracetam interaction with neuroleptics in psychopharmacological tests. Neuropsychobiology. 1986;19:93\u201396.", "ArticleIdList": ["2884593"]}, {"Citation": "Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther. 1993;57:1\u201378.", "ArticleIdList": ["8099741"]}, {"Citation": "Ezrin-Waters C, Muller P, Seeman P. Catalepsy induced by morphine and haloperidol: effects of apomorphine and anti-cholinergic drugs. Can J Physiol Pharmac. 1976;54:516\u20139.", "ArticleIdList": ["10058"]}, {"Citation": "Moore NA, Blackman A, Awere S, Leander JD. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur J Pharmacol. 1993;237:1\u20137.", "ArticleIdList": ["8359205"]}, {"Citation": "Jackson DM, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmac Ther. 1994;64:291\u2013369.", "ArticleIdList": ["7878079"]}, {"Citation": "Horacek J. Novel antipsychotics and extrapyramidal side effects: Theory and reality. Pharmacopsychiatry. 2000;33(Suppl 1):34\u201342.", "ArticleIdList": ["11072763"]}, {"Citation": "Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79\u2013104.", "ArticleIdList": ["15289815"]}, {"Citation": "Bourin M, Nic Dhonnchadha BA, Colombel MC, Dib M, Hasco\u00ebt M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res. 2001;124:87\u201395.", "ArticleIdList": ["11423169"]}, {"Citation": "Turnbull G, Bebbington P. Anxiety and the schizophrenic process: clinical and epidemiological evidence. Soc Psychiatr Epidemiol. 2001;36:235\u201343.", "ArticleIdList": ["11515701"]}, {"Citation": "Cao BJ, Rodgers RJ. Dopamine D4 receptors and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze. Eur J Pharmacol. 1997;335:117\u201325.", "ArticleIdList": ["9369363"]}, {"Citation": "Sakamoto H, Matsumoto K, Yukihiro O, Nakumura M. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent. Pharmacol Biochem Behav. 1998;60:873\u20138.", "ArticleIdList": ["9700971"]}, {"Citation": "Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171\u201380.", "ArticleIdList": ["11518637"]}, {"Citation": "Moore NA. Behavioural pharmacology of the new generation of antipsychotics agents. Br J Psychiatry Suppl. 1999;38:5\u201311.", "ArticleIdList": ["10884895"]}, {"Citation": "Kennedy B. Experimental approaches to the detection of anxiolytic activity in the rat. Ir J Med Sci. 1978;147:38\u201342.", "ArticleIdList": ["567631"]}, {"Citation": "File SE. The contribution of behavioral studies to the neuropharmacology of anxiety. Neuropharmacology. 1987;26:877\u201386.", "ArticleIdList": ["2821431"]}, {"Citation": "Dalvi A, Rodgers RJ. Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head-dipping but not the disinhibition of open-arm avoidance. Pharmacol Biochem Behav. 1999;62:727\u201334.", "ArticleIdList": ["10208379"]}, {"Citation": "File SE, Wardill GA. Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacology (Berl.) 1975;44:53\u20139.", "ArticleIdList": ["1197580"]}, {"Citation": "Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol. 1998;350:21\u20139.", "ArticleIdList": ["9683010"]}, {"Citation": "Ohl F, Roedel A, Storch C, Holsboer F, Landgraf R. Cognitive performance in rats differing in their inborn anxiety. Behav Neurosci. 2002;116:464\u201371.", "ArticleIdList": ["12049327"]}, {"Citation": "Nic Dhonnchadha BA, Bourin M, Hascoet M. Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res. 2003;140:203\u201314.", "ArticleIdList": ["12644293"]}, {"Citation": "Isogawa K, Fujiki M, Akiyoshi J, Tsutsumi T, Horinouchi Y, Kodama K, Nagayama H. Anxiety induced by repetitive transcranial magnetic stimulation is suppressed by chronic treatment of paroxetine in rats. Pharmacopsychiatry. 2003;36:7\u201311.", "ArticleIdList": ["12649768"]}, {"Citation": "Costa-Campos L, Dassoler SC, Rigo AP, Iwu M, Elisabetsky E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol Biochem Behav. 2004a;77:481\u20139.", "ArticleIdList": ["15006458"]}, {"Citation": "Costall B, Naylor RJ. Anxiolytic effects of 5-HT3 antagonists in animals. In: Rodgers RJ, Cooper SJ, editors. 5-HT1A Agonists, 5-HT3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. Chichester: John Wiley and Sons; 1991. pp. 133\u201358."}, {"Citation": "Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70:83\u2013244.", "ArticleIdList": ["12927745"]}, {"Citation": "Costall B, Naylor RJ. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol. 1995;116:2989\u201399.", "ArticleIdList": ["PMC1909209", "8680734"]}, {"Citation": "Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav. 2002;71:555\u201368.", "ArticleIdList": ["11888547"]}, {"Citation": "Roth BL, Shapiro DA. Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin Ther Targets. 2001;5:685\u201395.", "ArticleIdList": ["12540278"]}, {"Citation": "Van Oekelen D, Luyten WHML, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 2003;72:2429\u201349.", "ArticleIdList": ["12650852"]}, {"Citation": "Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci. 2001;21:750\u20137.", "ArticleIdList": ["PMC6763826", "11160454"]}, {"Citation": "Louren\u00e7o Da Silva A, Hoffmann A, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology. 2003;48:27\u201330.", "ArticleIdList": ["12886037"]}, {"Citation": "Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001;420:33\u201343.", "ArticleIdList": ["11412837"]}, {"Citation": "Dunn RW, Corbett R, Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and elevated plus maze. Eur J Pharmacol. 1989;169:1\u201310.", "ArticleIdList": ["2574684"]}, {"Citation": "Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia. 2002;43(Suppl 2):19\u201324.", "ArticleIdList": ["11903478"]}, {"Citation": "Torta R, Monaco F. Atypical antipsychotics and serotonergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia. 2002;43(Suppl 2):8\u201313.", "ArticleIdList": ["11903476"]}, {"Citation": "Alldredge BK. Seizures risk associated with psychotropic rugs: clinical and pharmacokinetic consideration. Neurology. 1999;53(Suppl 2):S68\u201375.", "ArticleIdList": ["10496236"]}, {"Citation": "Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol. 1969;95:294\u2013330.", "ArticleIdList": ["4981856"]}, {"Citation": "Cain DP. Long-term potentiation and kindling: how similar are the mechanisms. Trends Neurosci. 1989;57:37\u201343.", "ArticleIdList": ["2471338"]}, {"Citation": "Costa-Campos L, Iwu M, Elisabetsky E. Lack of pro-convulsant activity of the antipsychotic alkaloid alstonine. J Ethnopharmacol. 2004b;93:307\u201310.", "ArticleIdList": ["15234769"]}, {"Citation": "Arvanov VL, Wang RY. A selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-d-aspartate-receptor mediated neurotransmission in the medial prefrontal cortical neurons in vitro. Neuropsychopharmacology. 1998;18:197\u2013209.", "ArticleIdList": ["9471117"]}, {"Citation": "Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, Weinberger DR. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400\u20133.", "ArticleIdList": ["12130784"]}, {"Citation": "Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology. 1994;44(Suppl. 8):S14\u201323.", "ArticleIdList": ["7970002"]}, {"Citation": "Meldrum BS. Neurotransmission in epilepsy. Epilepsia. 1995;36:S30\u201335.", "ArticleIdList": ["23057108"]}, {"Citation": "Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol. 1998;54:581\u2013618.", "ArticleIdList": ["9550192"]}, {"Citation": "Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev. 2000;31:288\u2013394.", "ArticleIdList": ["10719155"]}, {"Citation": "Rakic P, Bourgeois JP, Goldman-Rakic PS. Synaptic development of the cerebral cortex: implications for learning, memory, and mental illness. Prog Brain Res. 1994;102:227\u201343.", "ArticleIdList": ["7800815"]}, {"Citation": "Daw NW, Stein PSG, Fox K. The role of NMDA receptors in information processing. Ann Rev Neurosci. 1993;16:207\u201322.", "ArticleIdList": ["8460891"]}, {"Citation": "Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral grey matter volume deficits in schizophrenia. Arch Gen Psychiatry. 1992;49:195\u2013205.", "ArticleIdList": ["1567274"]}, {"Citation": "Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003;169:215\u201333.", "ArticleIdList": ["12955285"]}, {"Citation": "Maurel-Remy S, Bervoets K, Millan MJ. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5HT2A receptors. Eur J Pharmacol. 1995;280:R9\u201311.", "ArticleIdList": ["7589172"]}, {"Citation": "Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141:267\u201378.", "ArticleIdList": ["10027508"]}, {"Citation": "Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse. 1999;34:266\u201376.", "ArticleIdList": ["10529721"]}, {"Citation": "Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000;295:226\u201332.", "ArticleIdList": ["10991983"]}, {"Citation": "Beljanski M, Beljanski MS. Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol. 1982;50:79\u201387.", "ArticleIdList": ["7075859"]}, {"Citation": "Beljanski M, Beljanski MS. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology. 1986;43:198\u2013203.", "ArticleIdList": ["3703465"]}, {"Citation": "Wright CW, Phillipson JD, Awe SO, Kirby GC, Warhurst DC, Quetinleclercq J, Angenot L. Antimalarial activity of criptolepine and some other anhydronium bases. Phytother Res. 1996;10:361\u201363."}, {"Citation": "Gandhi M, Vinayak VK. Preliminary evaluation of extracts of Alstonia scholaris bark for in vivo antimalarial activity in mice. J Ethnopharmacol. 1990;29:51\u20137.", "ArticleIdList": ["2345460"]}, {"Citation": "Demichel P, Roquebert J. Effects of raubasine stereoisomers on pre- and postsynaptic \u03b1-adrenoceptors in the rat vas deferens. Br J Pharmacol. 1984;83:505\u201310.", "ArticleIdList": ["PMC1987108", "6091834"]}, {"Citation": "Roquebert J, Demichel P. Inhibition of the \u03b11- and \u03b12-adrenoceptor-mediated pressor response in the pithed rats by raubasine, tetrahydroalstonine and akuammigine. Eur J Pharmacol. 1985;106:203\u20135.", "ArticleIdList": ["6099269"]}, {"Citation": "Shimazawa M, Chikamatsu S, Morimoto N, Mishima S, Nagai H, Hara H. Neuroprotection by Brazilian Green Propolis against In vitro and In vivo Ischemic Neuronal Damage. Evid Based Complement Alternat Med. 2005;2:201\u20137.", "ArticleIdList": ["PMC1142190", "15937561"]}, {"Citation": "Lindequist U, Niedermeyer THJ, J\u00fclich WD. The pharmacological potential of mushroom. Evid Based Complement Alternat Med. 2005;2:285\u201399.", "ArticleIdList": ["PMC1193547", "16136207"]}]}], "History": [{"Year": "2005", "Month": "8", "Day": "19"}, {"Year": "2005", "Month": "12", "Day": "26"}, {"Year": "2006", "Month": "3", "Day": "22", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "3", "Day": "22", "Hour": "9", "Minute": "1"}, {"Year": "2006", "Month": "3", "Day": "22", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "3", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["16550222", "PMC1375234", "10.1093/ecam/nek011"]}}], "PubmedBookArticle": []}